Under acquisition terms announced Monday, AstraZeneca will pay $425 million up front for all outstanding equity of privately held EsoBiotec. The Cambridge, England-based pharmaceutical giant could ...

Building on the momentum of the last two Cambridge Wide Open Days, the event will run from 9 - 13 th June 2025, offering an immersive experience to global investors, ecosystem CEO’s and employees, sci ...

Cambridge: Harbour BioMed, a global biopharmaceutical company has announced a global strategic collaboration with AstraZeneca ...

AstraZeneca makes a deal to buy another biotech company, this one with a price tag that could reach $1 billion.

AstraZeneca, headquartered in Cambridge, could pay up to $1 billion on a cash and debt-free basis for Belgian company ...

The lab will offer arrayed CRISPR screening for chronic disease through collaborations with researchers from across the U.K.

ELRIG meeting on Therapeutic Oligonucleotides brings together esteemed scientists from academia, industry, and other members ...

HONG KONG, LONDON] Ever since AstraZeneca shocked investors in October with news its China chief was under investigation, the ...

The transaction is expected to close in the second quarter of 2025, which will include AstraZeneca will buying all ...

CAMBRIDGE, UK] Drugmaker AstraZeneca said on Monday (Mar 17) it will buy biotechnology firm EsoBiotec for up to US$1 billion.

(Alliance News) - AstraZeneca PLC on Tuesday reported positive new study results for its lung cancer drug Tagrisso, strengthening its position as a "backbone" treatment for patients with EGFR-mutated ...

AstraZeneca’s EsoBiotec acquisition is the latest in a series of deals struck by the pharma giant to secure a place in the next wave of cell therapies for cancer and immune-mediated diseases.